Linked Life Data

8375428

Source:http://linkedlifedata.com/resource/pubmed/id/8375428

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:dateCreated
1993-10-21
pubmed:abstractText
The advance of Parkinson's disease has been suspected to be an outcome of oxidative stresses related to the metabolism of dopamine. Several recent studies have tested whether deprenyl (selegiline) or alpha-tocopherol (vitamin E) might attenuate the progression of Parkinson's disease. Although preliminary results of an 800-patient controlled clinical trial (DATATOP) suggested in 1989 that neuroprotection might be achieved with deprenyl, more recent analysis has questioned this conclusion. The apparent protective effect of deprenyl is lost after 1 year of treatment, and the drug's symptomatic antiparkinsonian effects confound an understanding of actions on the underlying disease. In the DATATOP trial, no neuroprotection was achieved with alpha-tocopherol. Methods developed in the deprenyl trials and newly discovered CSF markers of Parkinson's disease may be useful tools for future investigations of neuroprotective strategies against Parkinson's disease.
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
0014-3022
pubmed:author
pubmed:issnType
Print
pubmed:volume
33 Suppl 1
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
24-30
pubmed:dateRevised
2007-11-14
pubmed:meshHeading
pubmed:year
1993
pubmed:articleTitle
Neuroprotection by anti-oxidant strategies in Parkinson's disease.
pubmed:affiliation
Wayne State University, School of Medicine, Detroit, Mich.
pubmed:publicationType
Journal Article, Research Support, U.S. Gov't, P.H.S., Review